

18th EAHP Congress – Paris 2013 **BEA - 001**

Réseau Latin de Médecine Intensive



Building up a regional and interdisciplinary network for better use of medicines in intensive care units

Pierre Voirol¹, Laurent Gattlen², Thierry Fumeaux³, Philippe Eckert⁴ (In the name of Sipharom)

1.Service of pharmacy University Hospital, Lausanne; 2.Service of adult intensive Care Medicine University Hospital, Lausanne; 3.Service of intensive Care, Regional Hospital Nyon ; 4.Service of intensive Care, Clinic La Source, Lausanne, Switzerland

Background

Clinical pharmacy in intensive care units (ICUs) showed beneficial effects on safety and economics.

The set up of a regional network including pharmacists, physicians and nurses of all ICUs seemed useful for the following reasons:

- Issues regarding medication use in ICU are similar in all hospitals.

- Patients are often transferred from a tertiary care hospital to a secondary one or vice versa.

- Health care givers move from a hospital to another one during their career

Materials and Methods

Sipharom involves now 13 hospitals. Each is represented by an ICU physician, an ICU nurse and a pharmacist.

The group meets twice a year. Then, each member has to implement the decisions in his/her hospital.

Evolution:

In 2007, an interdisciplinary group, **Sipharom**, was set up in order to create a network in the French and Italian speaking parts of Switzerland.

Projet Purpose

The goals of the project are:

- exchange of data on drug administration in ICUs
- sharing of knowledge and skills
- establishing standards for the administration of drugs

Creation of Sipharom (5 centres) 2007

2007-2012 Integration of new sites

- Integration of Sipharom as a unit of a 2010 medical network of all ICUs of the Frenchand Italian-speaking parts of Switzerland (RLMI)
- Most of the 13 sites members of Sipharom 2012 are represented by a physician, a nurse and a pharmacist.



Sites members of Sipharom

Results

Four main axes have been developed:

Harmonisation of the dilution and preparation of intravenous drugs: 1) 52 standard dilutions have been defined. This led to collaborations with industries in order to obtain ready-to-use preparations at the defined dilutions.

Examples of dilutions:	Brand Name	Generic name	DECISION OF SIPHAROM
	ACTRAPID	Insuline	0,5 ml = 50 UI + Dextrose 5 % or NaCl 0,9% ad 50 ml. 1 ml/h = 1 Ul/h.
	ADALAT	Nifedipine	5 mg (1 x 50 ml/5 mg), PURE
	ADRENALINE	Epinephrine	15 mg (1,5 x 10 ml/10 mg) + 35 ml Dextrose 5% 1 ml/h = 5 μg/min
	ADRENALINE	Epinephrine	3 mg (3 x 1 ml/1 mg) + 47 ml NaCl 0.9% 1 ml/h = 1 mcg/min
	AGGRASTAT	Tirofiban	12.5 mg (1 Flex de 250 ml), PURE 1 ml/h = 50 μg/h
	CATAPRESAN	Clonidine	2amp.=300mcg=2ml + 22ml NaCl 0.9% 1ml=12.5 mcg (300mcg/24h=1ml/h)

Harmonisation of the labelling of syringes: 2)

Definition of the minimal list of elements that labels have to include (based on the available international guidelines and norms).

Minimal list of elements required on labels

1. Preparation / Dilution

3) **Exchange of critical data**

> Messages of alerts, problems of stability or of physico-chemical compatibilities



- 2. Highly relevant information (e.g. limited stability / To be protected from light)
- 3. Date / Time of preparation / signature(s)
- 4. Brand name
- 5. Generic name
- 6. Dose-speed of perfusion

4) Drafting of joint guidelines on drug use within the network

Benefits of standardisation

Nurses:

Univocal documents

Simplicity in drug preparation and administration

Physicians:

Expected impact of the network

Impact on safety

Decrease of risk during transfer of patients

Less habits to change when a care-giver (physician or nurse) move to another hospital

Reflection on practices and of the way of prescribing

Pharmacists :

Simplification in the elaboration of reference documents (concentration, stability)

Simplification in the realisation of compatibility analysis

Discussion and conclusions

Establishing a network is an effective way of increasing the exchange of expertise.

It can lead to the simplification and harmonization of practices and therefore help reducing risks and medication errors and limit problems related to the movement of patients and caregivers.

Pharmacists have to be the driving force of such interdisciplinary projects focusing on drug use.

Standardisation of medication use

Financial impact

Weight of the network when negotiating with industries

Anne-Laure Blanc

Members of the network

Sion	Pierre Turini	Chablais	Natalie Schai
	Muriel Joris-Frasseren	Morges	Anne Bezançon,
	Emmanuel Benoît		Florence Prudhomme
Jura	Alain Kocher		Corinne Chalet
	Norbert Croce	Fribourg (HFR)	Vincent Ribordy
	Juliane Fringeli		Marianne Maus
Geneva	Didier Tassaux	Yverdon	François Lapres
	Claude Guegueniat-Dupessey		Renaud Pichon
	Thérèse Siegrist	Payerne	David Chabanel
Lausanne	Philippe Eggimann		Jean-Paul Charlaine
Pierre Voirol	Laurent Gattlen, Isabelle Maillard		Renaud Pichon
		Neuchâtel –	Denise Njemba-Freiburghaus
Nyon	Thierry Fumeaux	La Chaux-de-Fonds	
(GHOL) Catherine Sermet Corinne Chalet		(HNE)	, Rima Ducommun
		Cardio Centro	Paola Rusca
Vevey	Damien Tagan (medicine)	Lugano	
(Riviera)	Gérald Seemater/Christine Lebrun (surgery)		
	Sophie Wallef (medicine)		
	Sandrine Gabens (surgery)		